Rosuvastatin as treatment for non alcoholic steatohepatitis (NASH) and highly active antiretroviral therapy (HAART)-dyslipidaemia: new treatment for global dangers.
Explore this paper's citation graph
- Type
- article
- Published
- 2006-01-01
- Cited by
- 6
- References
- 5
- OpenAlex
- https://openalex.org/W16223568
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:38906071
Keywords
Political science, Humanities, Philosophy
References
- Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
- Cardiovascular risk and body-fat abnormalities in HIV-infected adults.
- The Safety of Rosuvastatin as Used in Common Clinical Practice: A Postmarketing Analysis
- Nonalcoholic fatty liver disease.
- Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study
Cited by
- Managing dyslipidemia in HIV/AIDS patients: challenges and solutions
- Pharmacological treatment of non-alcoholic steatohepatitis: The current evidence
- Emerging drugs for non-alcoholic fatty liver disease
- The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges
- Treatment of patients with non-alcoholic fatty liver disease: current views and perspectives.
- Statins for treatment of fatty liver disease: Recent advances
Related papers
No related papers recorded.